CALYPTE BIOMEDICAL CORP (CBMC) - Description of business

Company Description
The company's current focus is on commercializing Aware HIV-1/2 Rapid Tests, primarily in international markets. Calypte plans to develop a complementary oral fluid test using an alternative antigen that will enable us to market a completely non-invasive screening and confirmation testing system for HIV-1/2. The company's overall plan is to expand significantly marketing and sales of HIV-1/2 Rapid Tests. The plan also includes developing and commercializing another lateral flow platform design suitable for over-the-counter applications, permitting entry into the HIV rapid test market in the United States and capable of expanding product line beyond HIV to a broader set of non-invasive diagnostic tests for other sexually transmitted diseases or diseases such as tuberculosis and malaria.